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Available online 12 April 2016Background: Magnetic resonance spectroscopy (MRS) is an established tool for in-vivo evaluation of the bio-
chemical basis of human diseases. On one hand, such lucid depiction of ‘live biochemistry’ helps one to decipher
the true nature of the pathology while on the other hand one can track the response to therapy at sub-cellular
level. Brain tumors have been an area of continuous interrogation and instigation for mankind. Evaluation of
these lesions by MRS plays a crucial role in the two aspects of disease management described above.
Scope of review: Presented is an overview of the window provided by MRS into the biochemical aspects of brain
tumors. We systematically visit each metabolite deciphered by MRS and discuss the role of deconvoluting the
biochemical aspects of pathologies (here in context of brain tumors) in the disease management cycle. We fur-
ther try to unify a radiologist's perspective of disease with that of a biochemist to prove the point that preclinical
work is themother of the treatment we provide at bedside as clinicians. Furthermore, an integrated approach by
various scientiﬁc experts help resolve a query encountered in everyday practice.
Major conclusions:MR spectroscopy is an integral tool for evaluation and systematic follow-up of brain tumors. A
deeper understanding of this technology by a biochemist would help in a swift andmore logical development of
the technique while a close collaboration with radiologist would enable deﬁnitive application of the same.
General signiﬁcance: The review aims at inciting closer ties between the two specialists enabling a deeper
understanding of this valuable technology.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Alterations in biochemical pathways involved in causation and those
resulting from occurrence of most human diseases have been under-
stood to an extent and still remain an intriguing problem for clinical sci-
entists. An assessment of the biochemistry of diseased human tissue can
provide useful information to aid in diagnosis and grading/staging of
diseases and, in monitoring of therapy. During the past two decades,
various techniques have been employed for metabolic proﬁling of nor-
mal and pathological tissue such as gas chromatography–mass spec-
trometry (GC–MC), Fourier transform-infrared spectrometry (FT-IR),
Liquid chromatography–mass spectrometry (LC–MS), Ramen spectros-
copy, thin layer chromatography and nuclear magnetic resonance
(NMR) spectroscopy [1]. Of these NMR mass spectrometry has the
best sensitivity and can identify up to 160 metabolite peaks [2]. Proton
MR Spectroscopy (H1MRS) is an extrapolation of the above technology,
focusing on the signals harnessed from spinning protons present in al-
most all molecules of human body. Best exploitation of the technique
has been done in evaluation of brain diseases especially for neuro-on-
cology. The technique remains of vital importance for an initial in-vivo
assessment of tumor characterization and grading, for follow-up on
treatment of tumorswhere obtaining a biopsy sample for ex-vivo exam-
ination is not possible and in situations where complete resection of a
tumor is not possible. Further H1MRS ﬁnds increasing application in
characterization of benign pathologies as well viz. tuberculoma, meta-
bolic and demyelinating brain diseases. Presented is an overview of
the basic principles, clinical extrapolations and applications of H1MRS
in the everyday clinical workﬂow, emanating from the unique window
of non-invasive tissue interrogation provided by MRS. As per the com-
mon parlance most examples pertain to neuroradiological applications
however that should not imply that equally.
2. Basic principles and technique of H1MR spectroscopy
2.1. Basic principle
The identiﬁcation of different chemicals in a tissue is based on
the fact that protons in different molecules with different atomic num-
bers precess at different frequencies. This difference in frequencies
(Larmor frequencies) is derived from the populace of electron cloud
surrounding the protons. As electrons are charged particles, they show
magnetic spin properties and when exposed to external magnetic ﬁeld
(B0) generates a small magnetic ﬁeld (B*). As a result, magnetic
environment surrounding the nucleus (and hence protons) is modiﬁed
minimally (expressed in parts per million of the external magnetic ﬁeld
(B0). Consequently, the resonance frequency of the nucleus, which is di-
rectly proportional to themagnetic ﬁeld it experiences, shifts. This phe-
nomenon is known as chemical shift and forms the basis of MR
spectroscopy [3].2.2. Techniques
There are two basic techniques utilized in MR spectroscopy; single
voxel techniques andmultivoxel techniques. Single voxel techniques em-
ploys PRESS (point-resolved spectroscopy) or STEAM (stimulated-echo
acquisition mode) sequences. STEAM offers advantages for the obtaining
short TE resonantmetabolites andmore effective water suppression. The
advantages of PRESS includes two-fold increase in obtained signal inten-
sity, and lesser susceptibility to motion, homonuclear coupling effects,
and eddy current [3,4]. Multivoxel imaging, also known as CSI (chemical
shift imaging) and MRSI (MR spectroscopic imaging) can obtain spectra
from a large volume of interest (VOI). CSI is better suited for evaluation
of brain tumors because of their larger size andmorphological andmeta-
bolic heterogeneity [5]. It also allows for comparison andnormalization of
pathologic spectra to spectra in normal tissue [6].
2.3. Choice of echo time (TE)
Short TE (20 to 40 ms) is useful in demonstrating myoinositol (MI),
glutamine/glutamate (Glx), amino acids, lactate, and lipids. They are
also useful in monitoring therapy for these diseases. Intermediate TE
(135 to 144 ms) provides information on fewer metabolites, however,
it has numerous advantages over short TE MRS such as differentiation
of lactate/alanine peak from lipids at 1.3–1.5 ppm (inversion of lactate
and alanine peaks occur at intermediate TE due to J coupling), better
delineation of NAA peak at 2.0 to 2.05 range (superimposed Glx peak
at 2 to 2.5 ppm on short TE), more accurate demonstration of lipid
peak and choline peak and less base line distortion compared to short
TE [3,6]. Long echo time (270 to 288 ms) produces less signal from
NAA, Cho and creatinine and can be used to depict lactate peaks accu-
rately; however, has lesser signal to noise ratio [7]. The current recom-
mendation is to acquire short TE and of time permits, intermediate TE
acquisitions. [6].
3. Which neurochemicals can be identiﬁed in H1 MRS spectrum of
normal brain and brain tumors
Every molecule exhibits its own ﬁngerprint on the chemical shift
spectrum. Understanding and identifying these frequency proﬁles
forms the ﬁrst step in evaluation of MR spectroscopic data.
3.1. Lipids
Beginning from the lower frequencies the ﬁrst resonant peak of
clinical interest are of lipids which resonate at 0.9 ppm (CH3) and
1.3 ppm ((CH2)n). These lipids are known as NMR visible mobile lipids
(ML). The rise of lipids detected in various cellular processes such as ne-
crosis, growth arrest, inﬂammation, malignancy and apoptosis. Mem-
brane lipids are usually not recognized on standard MRS unless
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these processes are predominantly saturated lipids believed to arise
from increased number of cytoplasmic vesicles especially in tissues
demonstrating necrosis and inﬂammation. The presence of lipid in lym-
phoma is postulated to arise from increasedmembranous component in
transformed lymphoid cells [9]. The presence of lipids in the spectra also
correlates well with the increased proportion of cells in S and G2 phase
of cell cycle signifying growth arrest [10,11]. Various in-vivo and in-
vitro MRS studies have showed that lipid peak obtained during apopto-
sis is predominantly polyunsaturated fatty acids which are primarily
constituents of mitochondrial membrane [12]. Lipid peaks have been
demonstrated in craniopharyngioma corresponding to high amounts
of cholesterol in the cyst ﬂuid [13].
3.2. Lactate
CH3 (methyl group) of lactate produces doublet peak at 1.33 ppm
which points upward at short TE and downwards at intermediate TE.
Lactate is an end product of glycolysis and increases rapidly during
hypoxia and ischaemia, in particular as a result of poor vascularity
and acquired resistance to hypoxia. Increased rates of lactate pro-
duction are associated with a range of tumors and usually signiﬁes
higher tumor grade and correlates with tumor metabolic activity.
Lactate peak usually is absent in low grade brain tumors and is con-
stituent of classical MR spectroscopy signature for a high grade pri-
mary brain tumor [14].
3.3. Alanine
Alanine results into a doublet peak at 1.47 ppm which inverts at in-
termediate TE due to J coupling. Another small singlet peak of alanine is
found at 3.93 ppm. Alanine peak is produced by transamination of pyru-
vate in hypoxic tissues showing increased glycolysis to prevent further
increase in lactate [15]. Amongst the brain tumors, meningiomas
show a distinct alanine peakwith variable sensitivity. Alanine inmenin-
giomas has been postulated to be a partial oxidation of glutamine [16].
or converted from increased pool of pyruvate due to inhibitions of the
enzyme pyruvate kinase by L-alanine [17]. Alanine peak is also elevated
in central neurocytoma and PNET [18–20].
3.4. Acetate and succinate
Acetate demonstrates a singlet peak at 1.92 ppm while succinate
shows a singlet peak at 2.42 ppm. Raised acetate and succinate levels re-
ﬂect anaerobic fermentation of pyruvate generated from glycolysis
where it undergoes carboxylation to form acetate and succinate. Al-
though these peaks might be slightly raised in brain tumors, clinically
the presence of markedly raised acetate and succinate peaks in the MR
spectra is useful for identifying brain abscesses thatmimic brain tumors
on conventional MR. [21,22].
3.5. N-acetyl aspartate (NAA)
N-acetyl aspartate (NAA) shows the largest peak of the spectra at
2.02 ppm as a singlet peak and another quadruplet peak at 2.5 ppm.
NAA peak also obtains contributions from N-acetyl aspartyl glutamate
(NAAG), glycoproteins, and amino acid residues in peptides. NAA is
the second most abundant amino acid in the brain and is synthesized
in mitochondria from aspartate and acetyl CoA and is transported into
the cytosol, where it is converted into aspartate and acetate by the en-
zyme aspartoacylase [3,23–26]. Although exact role of NAA in human
brain metabolism is uncertain, on the animal model studies it is postu-
lated to be involved in lipogenesis pathways, coenzymeA (CoA) interac-
tions [27–28]. Immunocytochemistry conﬁrms that NAA is located
primarily in neuronal tissues, hence can be used a surrogate marker
for neuronal density and integrity. In all the pathologies causing axonalloss includingmalignant or benign tumors, NAA is markedly reduced or
even absent. Lack of the biosynthetic enzyme for NAA, Asp-NAT (aspar-
tate N acetyltransferase)within the brain tumors is deemed as an expla-
nation for the lack of NAA signals [29]. Central neurocytoma, an
uncommon neuronal tumor, have been reported to exhibit detectable
NAA peak, although with decreased NAA/Cr [20,30]. NAA peaks have
also been used in predicting the histological type of the hypothalamic
hamartomaswith higher NAA in the hamartomaswithmainly neuronal
content compared to those with glial content [31].3.6. GLX
GLX consists of glutamate (glu), glutamine (gln) and GABA peaks.
Beta CH2 and Gamma CH2 moieties produce 2.0–2.46 ppm and alpha
CH group at 3.6–3.8 ppm. Glx complex has been observed in
peritumoral brain edema which is consistent with underlying demye-
lination and neuronal loss [32]. GLX can aid in differentiation of
oligodendroglioma from astrocytomas as it is reported to be signiﬁcant-
ly higher in oligodendrogliomas [33].3.7. Creatine
Creatine peak is seen at 3.03 ppm with primary contributions from
creatine and phosphocreatine and minor contributions from GABA,
lysine, and glutathione [34,35]. Another creatine peak is observed at
3.93 ppm. Cr signal is a marker for intracellular energy states as it stores
high energy phosphates. In the clinical MR spectroscopy Cr peak is
utilized as internal reference standard for characterizing other peaks
as its level is high and relatively comparable in different tissue
types of brain [36]. However, literature suggests that glial tumors
show 15–40% reduction in Cr levels. Similar data has been reported in
various other tumors as well, such as meningotheliomatous meningio-
mas which shows approximately 20% reduction in total creatine [37,38].
Total creatine content is signiﬁcantly low in non-neuroectodermal
tumors such as brain metastases compared to neuroectodermal tumors
[37].3.8. Choline containing metabolites (CCM)
The Choline (cho) resonance is present approximately at 3.2 ppm
and 3.52 ppm. The resonance is attributed to trimethyl ammonium res-
idues of free choline (3.21 ppm), phosphorylcholine (3.23 ppm),
glycerophosphorylcholine (3.24 ppm) and other metabolites such as
carnitine [39]. These frequency assignments of individual Cho constitu-
ents have been tentatively assigned by various researchers; however, it
is yet unresolved by scanners approved for clinical use. Cho is a salient
component of the Kennedy pathway, involved in genesis of phospholip-
id of the cell membranes. Cho is phosphorylated by Choline Kinase (CK)
to from PCho which reacts further with CTP to yield CDP-choline.
Phosphatidylcholine (PC) then results from the reaction of CDP-
choline with diacylglycerol [40]. The enzyme Choline Kinase is
overexpressed in several brain tumors and hence the presence of
choline peak in MRS spectra reﬂects increased cell membrane synthesis
and thus increased cellularity [41,42]. Miller and colleagues report that
the CCM peak obtained in brain tumor specimen correlates with Cho,
PCho, GPCho but not phosphatidyl choline [41].
Different authors have suggested different approaches to quantita-
tive assessment of cholinepeak. Some recommendCho/cr ratio compar-
ison with the contralateral normal parenchyma [43] whereas others
have reported better correlation of Cho/NAA with the tumor grade
[44,45]. Some studies have emphasized that even NAA and Cr levels de-
crease during tumor progression producing erroneous underestimation
of tumor progression using these ratios [46].
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Taurine shows two triplet peaks at 3.25 and 3.43 ppm. It is an inhib-
itory neurotransmitter that activates GABA-A receptors or strychnine-
sensitive glycine receptors [47]. Increased taurine is seen in PNET,
medulloblastoma, pituitary microadenoma and metastatic renal cell
carcinoma. High levels in medulloblastoma points towards morphoge-
netic similarities between medulloblastoma and retinoblastomas as
retina contains one of the highest levels of taurine owing to the
presence of its high afﬁnity transport system [48,49].
3.10. Myoinositol
Myoinositol produces at a quadruplet peak at 3.55 ppm. This is be-
lieved to be an osmolyte that is found primarily in astrocytes. In tumors,
myoinositol is involved in osmoregulation and volume regulation. In-
creased levels of mI are believed to reﬂect increased numbers of glial
cells, which have been reported to contain high levels of mI, and in par-
ticular have been reported to be high in grade II gliomas [5]. Castillo and
colleagues have observed that myoinositol is relatively higher in low-
grade gliomas (grade II gliomas) and lower in higher grade tumors
such as anaplastic astrocytoma (grade III) and glioblastomamultiforme
(grade IV gliomas) [50]. Krieger and colleagues have reported that MI
detectedwithin an intraventricular tumor in a pediatric patient suggests
choroid plexus papilloma [51].
3.11. Glycine
Glycine is an amino acid which resonates at 3.55 ppm. High
levels of glycine are found in medulloblastoma, ependymoma,
glioblastomas and central neurocytoma [52]. Studies show that
high glycine synthesis in gliomas is due to highly activated serine
hydroxymethyltransferase (SHMT) or deﬁciency of hypoxan-
thine–guanine phosphoribosyltransferase within the glioma cells
[53–55]. Regardless of necrotic component glycine peak isFig. 1. H1MRS spectra acquired at intermediate TE (135ms) shows elevated choline at 3.2
and a decreased NAA peak at 2.02, presence of an inverted lactate peak at 1.3 indicates
anaerobic metabolism. Note the presence of elevated myo-inositol (mI) at 3.56. Such a
spectra correlates well with the possibility mentioned above as less aggressive
metabolism on MRS corresponds to a moderate to low grade (WHO) tumor with
elevation of mI correlating to possibility of an oligodendroglial tumor.signiﬁcantly high in glioblastoma, differentiating them from meta-
static lesions [37].
3.12. Glucose
(C2–C6 protons) resonate in 3.43–3.8 ppm range but the signals are
usually low and undetectable at 1.5 T magnets except for some low
grade glioma [56].
4. The spectra of different brain tumors
4.1. Intraparenchymal tumors: biochemical milieu of glial tumors (Fig. 1)
MR spectra of glial tumors show decreased total creatine, nearly ab-
sent to markedly reduced NAA, raised choline and choline containing
compounds and a prominent glycine peak [37]. Ex-vivo studies have
shown raised levels of PEA in the glioma cells which can be attributed
to breakdown of phosphatidyl-ethanolamine in order to produce DAG
(diacyl glycerol) which acts as a second messenger system to invoke
cellular proliferation via phospholipase c [57]. Differentiation of glial tu-
mors from cerebralmetastasis can be obtained with the hypothesis that
the peritumoral edema surrounding the brain metastasis is purely
vasogenic whereas the edema surrounding high grade gliomas shows
tumoral inﬁltration. Elevated choline and reduced creatinine can be
found in peritumoral edema in gliomas compared to metastases [58].
MRS may also aid in identiﬁcation of cerebral metastatic origin. An in-
teresting study [59] has reported that secondaries from colorectal carci-
noma metastases show a higher lipid content and suggest a threshold
value of 2 for lipid/creatine ratio for its identiﬁcation.
A lipid dominated spectrum in the absence of tumoral necrosis is
found in lymphomas which are suggested to be due to macrophase ac-
cumulation along with increased membranous component in trans-
formed lymphoid cells containing high levels of mobile lipids [9].
Another consistent ﬁnding demonstrated by brain lymphomas is the in-
crease in choline resonance within the tumor and peritumoral areasFig. 2.H1MRS spectra acquired at intermediate TE (135ms) in a pediatric brain stem tumor
diagnosed as glioma. A non-speciﬁc spectra with an elevated choline at 3.2 and a
decreased NAA peak at 2.02 with presence of a lipid peak at 1.3. Though these features
are non-speciﬁc however presence of lipid with elevation of choline indicates an
aggressive nature of tumor (which may point towards grade shift). The diagnosis of
pediatric brain stem glioma remains obvious on imaging, the need of MRS if at all is for
grading of tumor.
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with threshold N7.09 observed in peritumoral regions of lymphomas
compared to glial tumors [69]. Lymphomas (Fig. 4) contain high PEA
content due to their high content in lymphatic tissues. Studies have
shown that PEA (phosphoryl ethanolamine) can be measured in-vivo
using 1H-decoupling technique [70].Fig. 4. H1MRS spectra acquired at intermediate TE (135ms) shows a spectra with an
elevated choline at 3.2 and a decreased NAA peak at 2.02. A prominent lipid peak at 1.3
in the presence of choline in a tumor indicates a possibility of lymphoma.4.2. Assessment of tumor grade (Fig. 2)
There are various studies that correlate choline levels with the grade
of glial tumors. Anaplastic astrocytomas (WHO grade III) are found to
have higher choline levels compared to low grade gliomas [60]. A ratio
of NAA/tCHO has been suggested as an accurate index to discriminate
between low grade and high grade (grade III) astrocytomas with
ratio N 1.6 predicting high grade gliomas [61,62]. Nevertheless there
are tangible discrepancies between the various studies correlating cho-
line levels and grade of gliomas. Lactate and lipids have been found in
high grade necrotic tumors but with variable consistency [60,63,64].
mI and glycine have been reported to play signiﬁcant role in grading
of the glial tumors. mI and glycine both appear at 3.5 ppm at short TE,
however mIdisappears at intermediate TE whereas glycine persists.
The level of glycine increases with the grade of glial tumor [63,65]
whereas the level of mI is high in low grade gliomas [60]. Candiota
et al. have developed an (mI + Gly) / CR index to grade glial tumors
while voxel is beingplaced on cellular part of themasswith the ratio de-
creasing signiﬁcantly between low grade glioma and high grade glio-
blastoma [66].4.3. Biochemical follow-up: relevance of MRS (Fig. 3)
MRS detected metabolite alteration can differentiate between dis-
ease progression and pseudo-progression/radiation necrosis, the latter
often resembling the former on conventional MR sequences. More ag-
gressive and revised treatment strategy has to be followed in tumor
progression while pseudo-progression/radiation necrosis mandates
observation on maintenance of the therapy [63]. About 1.7 to 1.8
times elevation of choline over either NAA or creatine may be utilized
to predict tumor progression with high accuracy [67,68]. This may be
complimented further by newer functionalMR techniques like diffusion
and perfusion weighted imaging.Fig. 3. H1MRS spectra acquired at intermediate TE (135ms) in a follow up case of
glioblastoma multiformis showing a prominent lipid peak at 1.3 ppm. No other
signiﬁcant peak is seen. Such a spectra in a post-therapy scenario remains quite speciﬁc
and help in differentiating an area of radiation necrosis from tumor recurrence.4.4. Spectroscopy in extraparenchymal mass (Figs. 5,6)
Most extraparenchymal tumors are benign meningioma which can
be easily identiﬁed on conventional MR sequences and CT scan with a
reasonable certainty. Urgent surgical intervention is not necessary and
patients can even be subjected to follow up. However before acquiring
such an approach, one must be mindful of the conditions that may
mimic these lesions that may not be benign. On MRS meningiomaFig. 5. H1MRS spectra acquired at low TE (30ms) shows an elevated alanine peak at
1.48 ppm proposing a possibility of meningioma. This is the ﬁrst peak seen in the
spectra (after lipid at 1.3) following which the NAA peak is reduced as meningioma is
an extra-axial tumor (the NAA seen is due to contamination from adjacent brain). Note
the prominent choline peak with a small creatine peak, which signiﬁes a hyppometabolic
tumor.
Fig. 6. H1MRS spectra acquired at intermediate TE (135ms) in a suspected metastasis (a
case of lung cancer) shows a non-speciﬁc spectra with an elevated choline at 3.2 and a
decreased NAA peak at 2.02, presence of an inverted lactate peak at 1.3 indicating
anaerobic metabolism. Signiﬁcant choline elevation indicates a high cell membrane turn
over while reduced NAA in an intra-axial tumor raises a suspicion of non-neurological
origin of the lesion. A situation where an intra-axial lesion also behaves like being
‘extra-axial’, as the NAA seen is due to voxel contamination from adjacent brain rather
than intra-tumoral signal, this can be noted while evaluating the voxel. This correlates
with a possibility of secondary deposit, especially so if a primary is known.
Fig. 7.MRS based proposed diagnostic algorithm for lesion differential diagnosis. The same s
imaging modalities like MRS should only to sought for correlation and problem solving purpos
175A. Verma et al. / BBA Clinical 5 (2016) 170–178shows prominent choline, nearly absent NAA or Creatine, and presence
of alanine [71]. Alanine is considered a speciﬁc for meningioma but its
identiﬁcation rate is variable from 32 to 100% [16]. A distinct peak
at 3.8 ppm has been suggested to reliably distinguish meningioma
from other malignant tumors such as metastases or glioma. This
peak has been suggested to correspond from Glx peak or from
phosphoethanolamine and amino acids by ex vivo studies [72].
A proportion of meningeal tumors such as atypical meningiomas,
atypical meningiomas, metastasis, and hemangiopericytomas are
aggressive in nature and need early treatment or resection [63].
Hemangiopericytomas show high peak at 3.56 ppm at short TE which
reduces in amplitude on long TE, corresponding to the myoinositol
whereas meningiomas do not show this peak [73]. Malignant meningi-
omas (atypical and anaplastic meningiomas) are reported to show
increased lipid peaks at short and long TE unlike the benign meningio-
mas [74,75]. Neurocytoma on the contrary is characterized by a glycine
peak at 3.55withmoderate elevation of choline and reduction of NAA&
creatine [52].
5. Limitations of MRS
MR spectroscopy is a technique with elegant physical principles and
clinical extrapolations yet it suffers with certain inherent limitations.
Physiological and non-physiological motion in human body causes an
increased line widths, overall frequency shifts, reduced peak areas,
and decreased quality of water suppression. These in turn lead to signal
degradation and diminution and a resulting noisy spectra which re-
mains inappropriate for clinical interpretation. Parallel imaging tech-
niques with motion correction/compensation would go a long way to
overcome the problem. Secondly, ﬁeld in-homogeneities due to intrin-
sic (patient related) and extrinsic (hardware related) factors are
reﬂected in the spectra as overlapping peaks. This causes poor peakhould however be done primarily on the imaging features, contribution from functional
es.
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active and passive shimming andby improving the overallﬁeld strength
of the basic magnet. Truncation artifacts or sinc wiggles remain a major
problem both in routine sequences as well as MRS. This causes baseline
undulations to increase to an extent ofmasking the peak. Better receiver
systems in RF antennae however can improve upon this limitation.
Lastly, micro-metabolites and metabolites with very short signal decay
time are difﬁcult to pick up on clinically available scanners and
mandate very high ﬁeld strength magnets and gradient systems for
detection [14,15,16,56,62].
6. Future directions
6.1. Multinuclear MRS
Several other nuclei have been applied and studied for MRS includ-
ing helium-3 (3HE), lithium-7 (7Li), carbon-13 (13C), oxygen-17
(17O), ﬂuorine-19 (19F), sodium-23 (23Na), phosphorus-31 (31P),
and xenon- 129 (129Xe). Of these nuclei 31P 19F, and 13C have exhib-
ited promise in the ﬁeld of neuro-oncologic applications [6,76]. 31PMRS
demonstrates seven major metabolite signals that are markers of ener-
gy consumption and transmittal within the brain cells and can be used
as surrogate markers of intracranial energy reserves. These metabolites
include three peaks of ATP, seen at −7.8, −16.3 and −2.7 ppm,
Phosphocreatine (PCr) at 0 ppm, Phosphodiester (PDE) at 2.6 ppm, in-
organic phosphate (Pi) at 4.9 ppm and Phosphomonoester (PME) at
6.5 ppm [77,78].While ATP, PCr and Pi compounds reﬂect cellular ener-
gymetabolism, PDE and PME constitute membrane phospholipids. 31 P
MRS also proves information about tissue pH by assessing the chemical
shift of the inorganic phosphate signal relative to the Phosphocreatine
signal. High grade gliomas show increased pH (alkalization), increase
in PME, decrease in PDE/α-ATP and relatively unperturbed PCr/α-ATP
or PCr/Pi ratios [3,6,79–81]. Meningiomas are characterized by an
alkalinity (pH 7.16), a decrease in phosphocreatine, and decreased
phosphodiesters [6]. However results are highly variable and some re-
searchers have debated the role of tissue pH in tissue characterization
as inconsistent and non-conclusive [82]. Recent studies have shown
that NMR spectroscopy can be used to monitor the functions of gene
products in various tumors. In a study on mice hepatoma cells compar-
ing HIF-1 deﬁcient tumor cells and those with wild type cells showing
similar T2 relaxationmeasurements, in-vivo and ex-vivo NMR spectros-
copy showed that HIF-1 deﬁcient cells showed ﬁvefold increase in total
ATP and triple times increased PDE/Pi ratio indicating that HIF-1
primarily increases rate of glucose metabolism rather than promoting
angiogenesis, as was previously thought [1,83].
Ultra-high-ﬁeld MRS (beyond 3 T): obtaining neurospectrometric
data at ultra high ﬁeld (4 T and 7 T) scanners offers two-fold advantage
of gain in signal to noise ratio (SNR) and increased chemical shift disper-
sion leading to consequent unambiguous identiﬁcation of the metabo-
lites [84]. Although the safety and clinical applications is still under
investigation, early research is promising and likely to have a place in
the future [6,85].
With the advent of high ﬁeld strength magnets and faster RF
detection systems, direct fourier transformation of free induction
decay generated (FID) signal is another technique [82,83]. Signal from
FID of H1 resonance, generated in solid state NMR, decays over micro-
seconds hence detection of the same to generate spectroscopic graph
should be fast and sensitive. FID generated MRS remains a useful tech-
nique to assess lesions with homogenous physio-chemical properties
as the limited number of frequencies decaying can be analyzed directly
and quantiﬁed accurately [82–85]. Further, improved spectral resolu-
tion offered by advanced MR hardware can lead to detection of
‘oncometabolites’ like D-2-hydroxy glutarate (2-HG) which accumu-
lates in IDH mutated gliomas due to ‘gain-in-function’ mutation in the
gene coding for the enzyme isocitrate dehydrogenase (IDH). Once
generated such metabolites compete with other energy metabolismenzymes and cause post-translational modiﬁcation of proteins thereby
rendering the tumoral milieu less sensitive to conventional therapy.
Detection of oncometabolites can help plan and prognosticate the ther-
apy in an evidence based manner. [86].
FunctionalMR spectroscopy is the new exciting advancementwhich
facilitates surveillance of temporal changes in metabolite concentra-
tions during various activities [3]. A technique named as PEPSI (proton
echo planar spectroscopic imaging) has been described by Richards
et al. for ultrafast repetitive spectroscopic assessment over a time period
[87].
7. Conclusion
MR spectroscopy has transitioned from its infancy and is no longer a
technological curiosity. With the advent of currently used high ﬁeld
scanners it has gained an unrivaled position in non-invasive assessment
of biochemistry of the brain tumors as well as in fundamental and clin-
ical research. Obviating the need for invasive chirurgical tissue sam-
pling, MRS continues to provide substantial and useful insight into
metabolomics of the brain tumors. We present a diagnostic algorithm
whichmay assist in sub-classiﬁcation of lesions once a list of differential
diagnosis has been tailored as per the imaging appearance (Fig. 7). It is
noteworthy that imaging appearance remains the primary tool to later-
alize, localize and characterize the lesion with MRS playing a signiﬁcant
role in sub-classiﬁcation of the biochemicalmileu of upfront and treated
brain tumors.
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